Innoviva (NASDAQ: INVA) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK.

Royalties Earned


Press Releases

Date Title and Summary
Toggle Summary Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe
LONDON --(BUSINESS WIRE)--Sep. 21, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta
Toggle Summary Innoviva Reports Second Quarter 2018 Financial Results
Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017. Net income attributable to Innoviva stockholders increased 55.4% from the second quarter of 2017 to $54.6 million , or $0.49 per diluted share. The Company intends to prepay $110 million of its Term B Loan.
Toggle Summary Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer
Hulme to execute capital allocation review and cost cutting initiatives of the board; will also oversee investigation into conduct of advisors to the board in connection with 2017 proxy contest BRISBANE, Calif. --(BUSINESS WIRE)--May 22, 2018-- Innoviva, Inc.
Toggle Summary Innoviva Reports First Quarter 2018 Financial Results
Royalties earned rose 28% to $55.8 million compared with the first quarter of 2017. Net income attributable to Innoviva stockholders increased 76% from the first quarter of 2017 to $29.6 million , or $0.29 per basic share. BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 26, 2018-- Innoviva, Inc.
Presentations & Events
There are currently no events to display.

Copyright West LLC. Minimum 15 minutes delayed.


Innoviva Investor Relations & Media

For business development inquiries,
please contact bd@inva.com.